^
    12d
    Targeted Photodynamic Activity of a Hyaluronic Acid-Protoporphyrin IX Complex via Receptor-Mediated Endocytosis. (PubMed, Chem Asian J)
    Further, the uptake of HA-1 in A549 cells was suppressed following the addition of free HA, indicating that its internalization occurred through CD44-receptor-mediated endocytosis. Moreover, the HA-1 complex exhibited better photodynamic activity against CD44-overexpressing cancer cells than both poly-L-lysine-1 complex and Photofrin, underscoring its potential as a targeted photosensitizer for photodynamic therapy.
    Journal
    |
    CD44 (CD44 Molecule)
    |
    Photofrin (porfimer sodium)
    21d
    Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer. (PubMed, Mol Pharm)
    The PS exhibits absorption at 665 nm (in vivo) and shows desired pharmacokinetics with limited skin phototoxicity in patients, compared to FDA-approved Photofrin...Combination of COX-2 inhibition with PDT or with BCG-immunotherapy showed an improved rate of tumor cures. Hence, HPPH-PDT in combination with COX-2 inhibitors not only reduces the expression of COX-2, IL-6, VEGF, and PGE2 but also enhances long-term tumor cure.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    Photofrin (porfimer sodium)
    26d
    Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (clinicaltrials.gov)
    P1, N=9, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Photofrin (porfimer sodium)
    3ms
    Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Active, not recruiting --> Terminated; low accrual
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Photofrin (porfimer sodium)
    4ms
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Photofrin (porfimer sodium)
    8ms
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    Photofrin (porfimer sodium)
    12ms
    Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    Photofrin (porfimer sodium)
    1year
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Terminated, Roswell Park Cancer Institute | Trial completion date: Feb 2030 --> Jul 2024 | Active, not recruiting --> Terminated; was paused by device company for a long period of time
    Trial completion date • Trial termination
    |
    Photofrin (porfimer sodium)
    1year
    Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Nov 2023 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Photofrin (porfimer sodium)
    over1year
    Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Recruiting --> Active, not recruiting | N=102 --> 52
    Enrollment closed • Enrollment change
    |
    Photofrin (porfimer sodium)
    over1year
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Nov 2023 --> Jul 2024
    Trial primary completion date • Endobronchial ultrasound • Metastases
    |
    Photofrin (porfimer sodium)
    over1year
    Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Active, not recruiting --> Terminated; Low accrual
    Trial termination • Metastases
    |
    Opdivo (nivolumab) • Photofrin (porfimer sodium)